BerGenBio

Carnegie Investment Bank is proud to have acted as joint manager in connection with BerGenBio ASA’s NOK 250 million rights issue.
 
The rights issue had strong support from existing shareholders and attracted interest from new investors. Net proceeds from the rights issue and exercised warrants will be used to further advance the company’s strategy for non-small cell lung cancer (“NSCLC”), severe respiratory infections and general corporate purposes.
 
Carnegie congratulates Martin Olin and Runde Skeie and the rest of the BerGenBio team with the transaction and we look forward to continuing our support of BerGenBio going forward.

Related articles

Norconsult
Investment Banking

Norconsult

Carnegie Investment Bank is proud to have acted as Joint Global Coordinator and Joint Bookrunner in...

Lifecare
Investment Banking

Lifecare

Carnegie Investment Bank congratulates Lifecare on the successful NOK 42.5 million private placement. Lifecare is developing the next generation...

NRC Group
Investment Banking

NRC Group

Carnegie Investment Bank is proud to have acted as Joint Lead Manager in connection with the...